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Abstract
Regulation of erythropoiesis is achieved by integration of distinct signals. Among these,
macrophages are emerging as erythropoietin-complementary regulators of erythroid development,
particularly under stress conditions. We investigated the contribution of macrophages for
physiological and pathological conditions of enhanced erythropoiesis. We utilized mouse models
of induced anemia, Polycythemia vera and β-thalassemia in which macrophages were chemically
depleted. Our data indicate that macrophages contribute decisively for recovery from induced
anemia as well as the pathological progression of Polycythemia vera and β-thalassemia by
modulating erythroid proliferation and differentiation. We validated these observations in primary
human cultures, showing a critical direct impact of macrophages on proliferation and enucleation
of erythroblasts from healthy individuals and Polycythemia vera or β-thalassemic patients. In
summary, we identify a new mechanism that we named “Stress Erythropoiesis Macrophage-
supporting Activity” (SEMA) that contributes to the pathophysiology of these disorders and will
have critical scientific and therapeutic implications in the near future.
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Introduction
Erythropoiesis is a dynamic and complex process during which erythroid progenitors
develop into enucleated red blood cells (RBCs). This multistep program1 is tightly regulated
to allow for constant replenishment of the highly abundant but short-lived RBCs. At steady
state erythropoiesis is mainly orchestrated by erythropoietin (Epo)2,3, although several
additional growth factors have been implicated in this process4–11. In addition, recent
evidences indicate that erythroid development is controlled by the neighboring
microenvironment. Erythroid cells have long been described to develop in a specialized
niche, the “erythroblastic island”12, composed of a central macrophage surrounded by
erythroblasts (EBs) at different stages of maturation13. Macrophages within these structures
are hypothesized to carry out essential physiological functions including iron recycling from
senescent RBCs and engulfment of nuclei extruded during erythroblast (EB)
enucleation13–16. Moreover, several lines of data suggest that macrophages also promote the
proliferation and survival of maturing EBs17–22. These effects seem to be dependent on EB-
macrophage contact22, suggesting that adhesion molecules or paracrine factors secreted
within the erythroid niche could be important effectors of these regulatory events. Consistent
with this hypothesis, macrophage or EB derived factors and different adhesion molecules
known to be important for erythroblastic island formation have been shown to regulate
erythropoiesis, particularly during embryogenesis or under conditions of stress
erythropoiesis9–11,14,18,23–25.
Even though erythropoiesis is an extremely active process, it can be further stimulated under
conditions of anemia, a process commonly known as stress eryhropoiesis. During stress
erythropoiesis, erythroid development extends to extramedulary sites (mainly the spleen and
liver), leading to expansion of the erythroid progenitor pool, recruitment of iron and
increased reticulocytosis and RBC production26,27. Unlike steady state erythropoiesis, which
seems to be relatively insensitive to microenvironmental changes9–11,14,18,24,25, stress
erythropoiesis is highly dependent on integrating signals from both the Epo/EpoR/Jak2/Stat5
axis28–30 and those activated within the EI, including BMP4/SMAD5 and integrin
signaling9–11,14,17,18,24–26,31. Interestingly, the pathophysiology of several disorders
resembles a “chronic” state of stress erythropoiesis. This includes two seemingly
dichotomous diseases, Polycythemia vera and β-thalassemia. Polycythemia vera is
characterized by extremely elevated erythrocytosis associated with the constitutively active
JAK2V617F mutation32–36. In contrast,β-thalassemia is characterized by anemia (due to low
β-globin synthesis) and expansion of the pool of erythroid progenitors37,38. Furthermore,
mouse models and human patients of both diseases share features characteristic of stress
erythropoiesis, including splenomegaly, expansion of the erythroid progenitor pool, and
elevated reticulocytosis36–41. These features stem from elevated activation of JAK2
downstream of EPOR (arising from the JAK2V617F mutation in Polycythemia vera or
elevated EPO levels in β-thalassemia) and can be limited by the administration of JAK2
inhibitors39,40,42–45. Even though these disorders can be classified as “chronic” stress
erythropoiesis conditions triggered by genetic lesions, the contribution of macrophages to
their pathophysiology has never been investigated.
In this study we explore the role of macrophages during stress and pathological
erythropoiesis. Our results indicate an incisive contribution of macrophages under different
stress conditions (anemia, EPO administration, Polycythemia vera and β-thalassemia).
Interestingly, macrophage-depletion studies in mouse models of Polycythemia vera or β-
thalassemia lead to a positive pathological outcome, reversing some key features linked to
both diseases. We further extend these observations to human samples and present evidences
supporting the need for direct contact between macrophages and erythroid progenitors for
these effects, suggesting that macrophage-erythroblasts adhesion interactions within the
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erythroblast island are essential for RBC development in physiological and disease
conditions.
Results
Clodronate-containing liposomes effectively eliminate splenic red pulp and bone marrow
macrophages
In order to study the role of macrophages during erythropoiesis, we depleted macrophages in
vivo by administering clodronate-encapsulated liposomes (referred hereafter as
“clodronate”)46. We confirmed that a single intravenous (IV) injection of clodronate
eliminated macrophages from the spleen and bone marrow (BM), as seen by a significant
decrease in F4/80 expression in these organs (See Materials and methods and
Supplementary Fig. 1). Moreover our data shows that this approach targets various subsets
of macrophages, as previously shown47, including those co-expressing the macrophage-
specific marker F4/80 and the adhesion molecule Vcam1, markers identifying macrophages
in the erythroblastic islands48. No significant effects could be seen on the percentage of
other myeloid lineages in these organs, suggesting that this approach is targeting specifically
the macrophage lineage (Supplementary Fig. 1).
Clodronate treatment markedly impairs the response to stress erythropoiesis in WT mice
To understand the role of macrophages during steady state erythropoiesis, WT mice were
treated with clodronate every two weeks for a total of 12 weeks. This treatment induced a
mild compensated iron-deficiency anemia, characterized by decreased hemoglobin and RBC
mean hemoglobin content (MCH), but not by reduced RBC (Supplementary Fig. 2a),
reticulocyte counts (not shown), spleen weight or significant changes in erythroid profiles by
FACS analysis (Supplementary Fig. 2b and 2c). The reduction of MCH, associated with
decreased transferrin saturation (not shown), indicates that chronic depletion of
macrophages at steady state reduces iron availability and hemoglobin synthesis, rather than
total RBC production. Moreover, clodronate-treated mice presented an elevated serum
erythropoietin compared to controls at the point when anemia started to develop
(Supplementary Fig. 2d), demonstrating that anemia was not associated with inappropriate
erythropoietin signaling.
Considering the limited contribution of macrophages to steady state erythropoiesis, we
investigated the potential impact of macrophage depletion under conditions of increased
erythropoiesis. Mice treated with clodronate while subjected to phlebotomy-induced anemia
(Clod (day 0) group) showed impaired recovery from anemia, with reduced reticulocytosis,
compared to phlebotomized control animals (Fig. 1a). This was associated with limited
erythropoiesis in the BM and spleen in clodronate-treated mice as compared to controls, as
seen by flow cytometry (Fig. 1c and Supplementary fig. 3a and b). A second group of mice
were treated with clodronate 4 days after induction of anemia (Clod (day 4) group), when
elevated erythropoietic activity and splenomegaly can be observed (Fig. 1b and 1c).
Compared to phlebotomized controls, Clod (day 4) mice exhibited a significant reduction in
reticulocyte counts, splenomegaly and in the percentage of erythroid precursors in the BM
and the spleen as early as day 6 (Fig. 1a–d and Supplementary Fig. 3c and 3d). Clodronate
administration in this setting also led to the appearance of a distinguishable
CD71highTer119low population in the flow cytometry profiles. This population revealed to
be mostly EBs (CD71highTer119lowCD45low) undergoing cell death (Fig. 1e and
Supplementary Fig. 4). These effects resulted in an impaired recovery from anemia in Clod
(day 4) animals (Fig. 1a), demonstrating that macrophages are important for both expansion
and maintenance of elevated erythroid activity in conditions of anemia. Based on these
observations, we also investigated whether macrophages are required to support increased
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erythroid activity following administration of human recombinant EPO (EPO). Indeed,
clodronate administration impaired erythroid expansion in the spleen as well as RBC and
reticulocyte production in response to EPO supplementation (Supplementary Fig. 5).
Altogether, these data strongly suggest that, under conditions of stress erythropoiesis,
signals from the erythroid niche seem to complement those downstream of the Epo-receptor
to fully support erythropoietic activity, independently from the hypoxic status.
Impairment of recovery from induced anemia in clodronate-treated mice is not associated
with impaired iron delivery to erythroblasts
Macrophages have been shown to play an important role in the maintenance of normal iron
homeostasis, as they recycle iron from senescent RBCs. Considering this, we aimed to
determine if slow recovery from anemia was associated with decreased iron availability for
erythropoiesis. We first analyzed the serum iron parameters and observed that, following
phlebotomy, clodronate-treated WT mice presented decreased serum iron and transferrin
saturation values compared to PBS controls (Supplementary fig. 6a and 6b), corroborating
the notion that macrophages play an important role on iron recycling. We then investigated
if the impaired recovery from anemia following macrophage depletion could be exclusively
attributed to limited iron availability. Considering that dietary iron and hepcidin have been
previously shown to play a crucial role during the recovery phase from phlebotomy-induced
anemia27, we hypothesized that dietary iron supplementation or mouse models of increased
dietary iron uptake (Hfe-KO and Hamp-KO) would be able to compensate for iron
deficiency following a single clodronate administration. In fact, clodronate treatment in
phlebotomized Hfe-KO, Hamp-KO or WT animals fed an iron-rich diet, did not alter iron
supply to erythroid cells, as seen by similarly elevated serum iron levels during all the
phases of the recovery in PBS- or clodronate-treated mice of each group (Supplementary fig.
6a and 6b). To a certain extent, elevated serum iron parameters allowed the iron-loaded
animals to recover faster than WT mice on regular diet from phlebotomy-induced anemia
(Supplementary fig. 6c). However, compared to WT controls, the faster recovery of
hemoglobin values in iron-loaded animals was predominantly associated with elevated
MCH levels rather than an increase in RBC numbers (Supplementary fig. 6c–e). In addition,
erythroid expansion in the bone marrow and spleen was impaired by macrophage depletion
in iron-loaded mice following phlebotomy (Supplementary fig. 7), likely accounting for the
delay in recovery from anemia compared to iron-loaded or non-iron loaded WT controls
(Fig. 1e and Supplementary fig. 6c–d). Altogether these observations indicated that elevated
serum iron levels are largely insufficient to compensate for the absence of macrophages in
sustaining erythroid proliferation and RBC synthesis during recovery from anemia. These
data supports the notion that iron is important to sustain stress erythropoiesis, but also that
pathways triggered by macrophages are quantitatively important in erythropoietic response
following phlebotomy-induced anemia, independently from the role of macrophages in
erythroid-iron recycling.
Clodronate improves phenotype of mice affected by Polycythemia vera
Considering the crucial role that macrophages play under conditions of increased
erythropoietic activity, we investigated whether macrophages are also involved in the
pathophysiology of Polycythemia vera utilizing a transgenic line (Jak2V617F/+) carrying a
Cre-inducible Jak2V617F mutation40. These animals exhibit a transplantable Polycythemia
vera-like phenotype, which is mediated by the constitutive activation of Jak240.
Accordingly, we generated a cohort of Polycythemia vera animals engrafting Jak2V617F/+/
VAV-Cre double transgenic BM into normal mice. As early as two weeks post-engraftment,
mice transplanted with Jak2V617F/+/VAV-Cre double transgenic bone marrow developed
features characteristic of Polycythemia vera, including elevated hematocrit (HCT), increased
RBC counts and reticulocytosis. In contrast to PBS-treated mice, weekly clodronate
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administration beginning 16 days post-engraftment rapidly normalized the HCT and RBC
counts in these animals (Fig. 2a). Furthermore, clodronate-treated mice showed significant
evidence of decreased erythropoietic activity as indicated by reduced reticulocytosis,
decreased extramedullary hematopoiesis (EMH) in the bone marrow and spleen,
splenomegaly (Fig. 2b–e) and the number of Epo-independent BFU-E, as assessed by
colony assay (Supplementary Fig. 8). The same reduction in erythrocytosis and EMH was
achieved when clodronate administration was initiated 2 months post-BMT, a point at which
the Polycythemia vera phenotype is fully established (not shown), indicating that
macrophage depletion not only prevents, but also reverses the phenotype in these animals.
Short-term clodronate treatment ameliorates IE and anemia in β-thalassemic animals
(Hbbth3/+)
Our results indicate that macrophages are required to support increased erythropoiesis under
“transient” (following phlebotomy or EPO administration) or “chronic” (as in Polycythemia
vera) stress conditions. Another disease in which erythropoiesis is constitutively enhanced to
compensate for the chronic anemia is β-thalassemia. However, erythropoiesis in this
disorder is ineffective, characterized by an increased number of erythroid progenitors that
fail to generate enough RBCs as a consequence of premature death and reduced
differentiation37–39. Therefore, we investigated how macrophages influence IE in a mouse
model of β-thalassemia intermedia (Hbbth3/+)49, exhibiting anemia and splenomegaly.
Strikingly, 40 hours after a single clodronate injection, Hbbth3/+ mice showed improvement
of their anemia, characterized by increased hemoglobin and RBC as compared to Hbbth3/+
control mice (Fig. 3a). Moreover, the spleen size was also significantly decreased by 32% in
clodronate-treated compared to PBS-treated Hbbth3/+ animals (Fig. 3b). Some of these
effects could be seen as early as 20 hours after clodronate administration (Supplementary
Fig. 9). In both cases, these improvements were not associated with increased apoptosis of
the erythroid progenitors (Supplementary Fig. 10), but rather with an improvement of IE, as
indicated by reduction in the number of erythroid progenitors and proportional increase in
differentiated erythroid cells in both the spleen and the BM (Fig. 3c–d and Supplementary
Fig. 11 and 12). In agreement, clodronate treatment led to a reduction in the number of
cycling EB in the spleen (Supplementary Fig. 13), possibly accounting for decreased
splenomegaly. These results indicated that, paradoxically, macrophages impair efficient
erythroid development in β-thalassemia. Interestingly, these changes were associated with
increased hepcidin expression in the liver along with decreased serum iron levels
(Supplementary Fig. 14), which have been shown to improve IE in Hbbth3/+ mice50. In order
to understand if the effect on IE seen after clodronate administration is solely mediated by
reduced iron availability50,51, we iron-loaded β-thalassemic animals by administration of
high-iron diet or by generating mice that lacked hepcidin expression (Hbbth3/+-Hamp-KO
mice). Considering that in mice, dietary iron absorption accounts for about 50% of iron in
circulation52,53, we hypothesized that dietary iron supplementation could suffice to
compensate for decreased iron recycling following clodronate administration. At steady state
we observed that serum iron values were elevated in both models compared to Hbbth3/+
controls. However, unlike the situation in non-iron-loaded Hbbth3/+ mice, macrophage-
depletion in iron-overloaded Hbbth3/+ animals did not lead to any decrease in serum iron
availability (Supplementary Fig. 15a and 16a). However clodronate-administration still
resulted in improvements in both erythroid differentiation (Supplementary Fig. 15b–d and
16b–d) and splenomegaly (28% reduction in iron supplemented Hbbth3/+ mice and 12%
reduction in Hbbth3/+-Hamp-KO mice), suggesting an iron-independent function of
macrophages in stimulating erythropoiesis. Furthermore we also tested if supplementation of
Hbbth3/+ animals with parenteral iron-dextran could compensate for the effect seen after
clodronate administration. While this treatment did not increase serum iron values at steady
state, it prevented drop of these parameters following clodronate administration in Hbbth3/+
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animals (Supplementary Fig. 17a). Even in this setting, macrophage-depletion resulted in a
reduction of EMH (Supplementary fig. 17b–d) and splenomegaly (30% reduction). While
the role of iron in ineffective erythropoiesis in β-thalassemia has been previously
shown50,51, our data suggest that macrophages further contribute for the development of
EMH and splenomegaly in this disorder, independently from modulation of erythroid iron
availability.
Chronic clodronate treatment improves IE and anemia in β-thalassemia intermedia
(Hbbth3/+)
In order to determine how long-term macrophage depletion affects IE, we administered
clodronate to Hbbth3/+ mice up to 12 weeks. This treatment led to a significant improvement
of anemia and RDW (Fig. 4a). Furthermore, despite an increase in the number of circulating
RBCs in clodronate-treated mice, reticulocyte counts decreased over time, indicating that
erythropoietic activity was reduced (Fig. 4a). This apparent contradiction was resolved when
we observed that macrophage depletion increased the RBC lifespan to levels similar to those
observed in normal mice (Fig. 4b). However, the increased lifespan of the RBCs in
clodronate-treated mice was not associated with deficient erythrophagocytosis, but rather
with an improvement in the RBC phenotype as indicated by a series of additional
observations: first, the lifespan of RBCs derived from clodronate-treated Hbbth3/+ mice was
significantly extended compared to that of RBCs derived from PBS-treated animals, after
transfusion into GFP-positive WT animals with an intact reticuloendothelial system (Fig.
4c); second, the morphology of RBCs was improved (Fig. 4d); third, the MCH of the RBCs
was decreased in clodronate Hbbth3/+ treated-mice (Fig. 4a), suggesting that these cells take
up less iron, with potential beneficial effects on hemichrome formation50,51. In fact, RBCs
derived from clodronate-treated Hbbth3/+ mice exhibited reduced accumulation of α-globin
chains in the RBC membrane compared to Hbbth3/+ PBS liposome-treated controls (Fig. 4e).
Chronic clodronate treatment markedly suppressed splenomegaly, with total spleen size
reversing within two months to levels comparable to WT mice (Fig. 4f). The decrease in
splenomegaly was erythropoietin-independent (Supplementary fig. 18), being associated
with a reduction of EMH and restoration of splenic architecture (Fig. 4g–h and
supplementary fig. 19).
Primary human macrophages stimulate proliferation and delay enucleation of primary
human erythroblasts
Considering the interesting data obtained in mouse models of Polycythemia vera and β-
thalassemia, we investigated how primary human macrophages influenced development of
human erythroblasts ex-vivo. For that we expanded hematopoietic progenitors from patients
affected by Polycythemia vera (JAK2V617F positive), β-thalassemia and healthy individuals
and evaluated their proliferative potential when differentiated into the erythroid lineage in
the presence of macrophages. Irrespective of their genotype, EB cultured in the presence of
macrophages exhibited increased proliferation compared to those cultured alone (Fig. 5a).
This effect was associated with an increased percentage of cells cycling as well as a
decreased number of apoptotic EB when macrophages where utilized in the co-culture
system (Fig. 5b and Supplementary Fig. 20). We then investigated if direct macrophage-
erythroblast contact was required for this effect, by performing trans-well experiments. We
observed that the positive effect exerted by macrophages on erythroid proliferation was
abrogated by 75% in the trans-well co-cultures, suggesting that direct macrophage-
erythroblast interaction is required (Fig. 5c), even though some secreted factors might also
be involved. We then looked at the effect of the co-culture on erythroid differentiation by
assessing the expression of different cell surface markers. First we observed that
macrophages did not have a dramatic effect on the morphological appearance of
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erythroblasts, and similarly did not significantly affect the expression of the erythroblast
developmental markers Glycophorin A (GPA), CD44, CD117 and Band-3 (Supplementary
fig. 21). However, when we looked at enucleation and beta1-integrin expression, we observe
that at latter time points (day 8), there was a significant reduction in the number of
enucleated EB in the co-cultures, as well as retention of higher beta1-integrin surface levels
in a greater number of EBs (Fig. 5d and supplementary fig. 22). These observations are
consistent with our results in the mouse models, supporting a model where macrophages
promote erythroid proliferation and survival, while reducing EB differentiation. Moreover,
our data further highlight the critical role of the erythroid microenvironment, particularly the
macrophage-EB interaction(s), in the regulation of pathological erythropoiesis, and extends
the relevance of our findings in human samples.
Discussion
Macrophages are historically classified as immunological cells whose main function is
immune surveillance. However, several lines of evidence suggest additional trophic
functions for macrophages in different tissues54. One such function is the regulation of
erythroid development14,17,18,22. However, no one has ever investigated the contribution of
macrophages to pathological erythropoiesis and evaluated the therapeutic potential of
targeting their function in disease states associated with disordered erythropoiesis.
Our present data underscore the central role that macrophages play under conditions of
increased erythropoietic activity, such as induced anemia or EPO administration. We
previously showed that iron availability is crucial for the recovery from induced anemia27.
Our data further expands on this hypothesis, supporting the notion that elevated iron supply
can be beneficial in conditions of anemia. Moreover, our results show that, even under
conditions where erythroid iron supply is elevated, lack of macrophages delays recovery
from induced anemia, indicating that macrophages play an important role in supporting
stress erythropoiesis independent from providing iron to EBs. Altogether our data
demonstrate that, even though EPO3,55 and iron are rightfully recognized as master
regulators of erythropoiesis, they are not sufficient to fully support EB proliferation and
survival during stress erythropoiesis. Under such conditions the iron-independent “Stress
Erythropoiesis Macrophage-supporting Activity” (SEMA) is also required for proper
erythroid activity (Fig. 6).
We further extended the concept of macrophage-dependent erythropoiesis to pathological
conditions associated with elevated erythropoietic activity, such as Polycythemia vera or β-
thalassemia. Polycythemia vera is a clonal stem cell disorder in which the somatic
JAK2V617F mutation36–41 leads to a hyperproliferative phenotype. While our data do not
question the importance of the JAK2V617F mutation for Polycythemia vera, it provides an
additional degree of complexity to this disorder. We clearly demonstrate that, macrophage-
depletion in mice carrying the Jak2V617F mutation reversed some of the key features of
Polycythemia vera, including splenomegaly, reticulocytosis, erythrocytosis and elevated
hematocrit. Furthermore, we show that proliferation of cells derived from JAK2V617F
patients is increased when they were co-cultured with macrophages. Thus, we propose a new
model for Polycythemia vera progression in which the JAK2V617F mutation functions as
primer for the Polycythemia vera phenotype, but a permissive niche and SEMA are required
for full manifestation of the erythroid phenotype in vivo (Fig. 6). This model represents a
clear parallel to the current understanding of tumor biology. Also in this case, an oncogenic
mutation is considered to be the primary event leading to tumorigenesis. However, the role
of tumor associated macrophages supporting tumor progression and metastatic spread is now
uncontested54. This is the first description of what we believe to be an important mechanism
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contributing for the pathophysiology of Polycythemia vera that could have significant
therapeutic implications for the management of this disorder.
Erythropoiesis in β-thalassemia is characterized by 4 pillars: (1) increased proliferation; (2)
ineffective differentiation, which are associated with modulation of the JAK-STAT
pathway37–39; (3) reduced survival of EBs; and (4) limited RBC lifespan37. All of these
features are modulated by macrophages, making the interpretation of our studies more
complicated. On the one hand, our data indicated that macrophage depletion directly
influences erythroid development in β-thalassemia by decreasing erythroid proliferation and
increasing their differentiation, leading to reduced reticulocytosis (as in stress erythropoiesis
and Polycythemia vera mice), splenomegaly and EMH (Fig. 6). The effect on erythroid
expansion and splenomegaly is seen very rapidly following macrophage depletion, pointing
to a direct effect of macrophages in modulating signaling pathways controlling erythroid
proliferation and differentiation. In agreement, we show that these effects are seen
independently from the effects of clodronate treatment in erythroid iron availability (in
Hamp-KO, and iron supplemented thalassemic mice). Moreover, we also demonstrate in
human samples, that macrophages directly promote proliferation and limit enucleation of
human primary erythroblasts. On the other hand, we show that clodronate treatment impairs
iron delivery to maturing erythrocytes, as seen by reduction of serum iron levels following
clodronate administration. Similarly to what was previously shown50,51, limited iron
availability likely contributes for a reduction in hemichrome formation, and consequently
increased RBC lifespan. Thus, despite the fact that production of reticulocytes decreases, the
number of RBCs is increased because their survival and lifespan are normalized (Fig. 6).
Altogether our data supports a model in which macrophages depletion positively influences
erythropoiesis in β-thalassemia by two distinct mechanisms: a) direct modulation of
erythroid activity by limiting SEMA; and b) reduced iron availability. We believe that
targeting these two pathways would be of greater therapeutic benefit than targeting each of
them individually.
In summary, our data support a model where SEMA stimulates signaling pathways that
complement Epo/EpoR/Jak2 signaling and iron supply and are essential for erythroid
expansion and differentiation (Fig. 6). Without this support the proliferative potential of
erythroid cells diminishes substantially. Thus, while loss of SEMA seems to be detrimental
during anemia in healthy individuals, it likely decreases the pathological features of
disorders associated with enhanced erythroid activity, like Polycythemia vera or β-
thalassemia. We believe that these findings are of great interest, as they could pave the road
for the identification of novel therapeutic approaches complementary to those currently
being employed in these disorders.
Online methods
Animals and procedures
Mice on a c57Bl/6 background were maintained and bred at the Weill Cornell Medical
College animal facility. All procedures were performed according to approved protocols.
We induced stress erythropoiesis in 2- to 5-month-old WT animals by phlebotomy (400ul/
25g body weight) performed under anesthesia on 3 consecutive days, followed by
administration of equal volume of normal saline, as previously described27. Recovery from
anemia was assessed by withdrawing 50–100 μl of blood every 2–3 days and performing
complete blood cell counts (CBCs). An iron-rich diet (supplemented with 2% carbonyl iron)
was given to a subset of mice one week prior phlebotomy. These animals were kept on the
high-iron diet throughout the recovery. We also stimulated erythropoietic activity WT mice
by daily intra-peritoneal (IP) administration of 50 units of hrEPO (Epogen, Amgen, CA) for
Ramos et al. Page 8
Nat Med. Author manuscript; available in PMC 2013 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
8 days. To determine how macrophages influence the response to these stress conditions, we
administered clodronate to phlebotomized or EPO-treated mice. Clodronate suspension was
prepared as previously described46 and administered intra-venous (100 μl) according to the
injection schemes summarized in Supplementary Fig. 23. We administered PBS-containing
liposomes in control animals for all experiments. Clodronate was provided by Roche
Diagnostics, Mannheim, Germany.
We utilized mice carrying a Jak2-V617F conditional knock-in40 crossed with animals
expressing cre-recombinase under the control of the hematopoietic vav regulatory
elements56 (VAV-Cre) to generate animals affected by Polycythemia vera. Jak2V617F/+/
VAV-Cre double-transgenic mice developed a Polycythemia vera-like phenotype, which
was transplantable, as previously demonstrated40. In order to generate large number of
animals affected by Polycythemia vera we performed bone marrow transplantation (BMT)
into lethally irradiated recipients. In brief, 3–5×106 BM cells from Jak2V617F/+/VAV-Cre
mice were transplanted by IV injection into the lateral tail veins of lethally irradiated
(9.5Gy) c57Bl/6 WT recipients. In order to evaluate the contribution of macrophages for
Polycythemia vera, we allowed the Polycythemia vera phenotype to develop following BMT
(about 2 weeks). Sixteen days post bone marrow transplant we started weekly IV
administration of 200 μl of clodronate- or PBS-liposomes for a total of four injections (see
Supplementary Fig. 23 for details). Progression of hematological parameters was monitored
by weekly CBCs.
We utilized Hbbth3/+ animals as a model of β–thalassemia intermedia49. The animals used in
this study were between 2 to 3 months of age. For some experiments (indicated in the figure
legends) Hbbth3/+ animals were generated by BMT similarly to what was previously
described55. Hbbth3/+-Hamp-KO were generated by transplanting 3–5×106 BM cells from
Hbbth3/+ mice into lethally irradiated Hamp-KO animals. Experiments with BMT mice were
started 2–3 months post-BMT. Macrophage depletion was performed by IV administration
of clodronate, PBS-liposomes being utilized as control. For short-term studies, we analyzed
animals 20 and 40 hours after a single clodronate injection (100 μl). Long-term macrophage
depletion was performed in Hbbth3/+ and WT mice by IV administration of lower doses of
liposomes (50 μl) every two weeks, for up to 12 weeks. We followed hematological
parameters by CBC throughout the treatment. For more details on clodronate administration
schemes please consult Supplementary Fig. 23. Iron supplementation (dietary or parenteral)
was performed as described in supplementary Fig. 15, 17 and 23.
Hematological studies
Hematological values were determined as previously described57. In brief, we collected
blood samples by retro-orbital puncture under anesthesia and CBCs were measured on an
Advia 120 Hematology System (Bayer, Tarrytown, NY).
Flow cytometry analysis of mouse erythroid cells
We harvested BM and spleen cells as previously described57. For erythroid analysis, we
incubated single cell suspensions with Fluorescein isothiocyanate (FITC)-labeled anti-
mouse CD71, Phycoerythrin (PE)-conjugated anti-mouse CD44 and Allophycocyanin
(APC)-conjugated anti-mouse Ter119 antibodies (BD Pharmingen, San Diego, CA) for 15
minutes on ice. Samples were washed with PBS supplemented with 1% BSA and acquired
in a FACSCalibur (BD) instrument equipped with a dual-laser. For determination of DNA
content, we first stained the cells with the cell-surface markers, washed and then re-
suspended in 300μl of diluted (1:5,000) DRAQ5 (Cell Signaling Technology) 10–15
minutes before running. For apoptosis analysis we stained single cell suspensions with PE
labeled anti-mouse CD71, APC-conjugated anti-mouse CD44 and Pacific Blue-conjugated
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anti-mouse Ter119 antibodies (BD Pharmingen, San Diego, CA) for 15 minutes on ice.
After washing, cells were incubated with 7AAD and FITC-labeled Annexin V (BD
Pharmingen) in 100μl of 1x binding buffer according to the manufacturer’s instruction. For
cell cycle analysis, we utilized the APC-BrdU flow kit (BD Pharmingen), according to the
manufacturer’s instructions. In brief, 1 mg of BrdU was administered to mice by IP injection
and BM and spleen were harvested 1 hour post BrdU administration. Single cell suspensions
were first incubated with FITC-labeled anti-mouse CD71, PE-labeled anti-mouse CD44 and
Pacific Blue-conjugated anti-mouse Ter119 antibodies (BD Pharmingen, San Diego, CA) as
described above. Following cell surface stain, we stained cells with 7AAD and APC-
conjugated anti-BrdU antibody as described in the kit manual. Samples were run in a FACS
Canto II system (BD) equipped with 3 lasers. Analysis was performed using flow-jo
software (Tree Star Inc., Ashland, OR).
Macrophage and myeloid analysis by flow cytometry
BM and spleen cells were harvested as previously described57. Single cell suspensions were
incubated with PE-conjugated F4/80 anti-mouse antibody (eBiosciences, San Diego, CA)
and FITC-labeled anti-mouse CD11b or Gr1 antibody (BD Pharmingen, San Diego, CA) in
30% mouse serum in PBS for 30 minutes on ice. For Vcam1 analysis, cells were first stained
with purified anti-mouse Vcam1 antibody (BD Pharmigen, San Diego, CA) in PBS, 1%
BSA for 30 minutes on ice. After washing, cells were stained with FITC Goat Anti-Rat Ig
(BD Pharmigen, San Diego, CA) for 30 minutes on ice and then washed once with PBS, 1%
BSA. F4/80 staining was performed with PE-conjugated F4/80 anti-mouse antibody as
described above. Samples were washed with 1% BSA in PBS and acquired in a
FACSCalibur (BD) instrument equipped with a dual-laser. Analysis was performed using
flow-jo software (Tree Star, Inc., Ashland, OR).
Measurement of RBC lifespan
RBC lifespan was determined by labeling RBCs with sulfo-NHS-biotin reagent (Pierce,
Rockford, IL) as previously described27,50. In brief, we injected mice with 1 mg of sulfo-
NHS-biotin intravenously. Aliquots of blood were stained with flourochrome-conjugated
streptavidin antibody and analyzed by flow cytometry at different time points for up to 2
weeks post sulfo-NHS biotin administration.
Measurement of Hbbth3/+ RBC survival in WT mice
To evaluate whether the lifespan of RBCs from clodronate-treated mice Hbbth3/+ mice was
extended compared to that of PBS-treated Hbbth3/+ mice in mice with an intact
erythrophagocytic system, we evaluated the survival of RBCs from these groups after
transfusion into GFP positive mice, as previously described50. For that we injected 400 μl of
blood from each Hbbth3/+ mouse into previously phlebotomized (about 400 μl) GFP positive
mice. Clearance of GFP-negative Hbbth3/+ RBCs from the peripheral blood of transfused
mice was measured by FACS every 6 days for up to 18 days.
Analyses of α– and β– globin chains in plasma and on RBC membranes
To visualize soluble as well as membrane-bound globins, we utilized triton acetic acid urea
(TAU) gel electrophoresis as previously described50,58,59. The fraction of sample loaded on
the TAU gel was adjusted considering CBC readings, so that the same number of RBCs
(150×106) was loaded in each lane.
Expansion of human CD34positive hematopoietic progenitors
Peripheral blood mononuclear cells (PBMCs) were separated by ficoll gradient and, after
extenssive washing with PBS, were resuspended in 600μl of 1% BSA in PBS. We then
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added 100 μl of anti-human CD34 beads for 15 minutes at 4°C, after which we passed the
cells through an LS magnetic column (Miltenyi Biotech) according to manufacturer’s
instructions. Eluted CD34 negative cells were processed for macrophage differentiation (see
below). CD34 positive cells trapped in the column were collected by removing the LS
column from the magnetic field and eluting with 5 ml of beading buffer. We expanded
CD34 positive hematopoietic progenitors in stem-span supplemented with 1% of CC100
cytokine cocktail (Stem Cell technologies), 2U/ml of hrEPO 100 μg ml−1 of streptomycin,
100 U ml−1 penicillin and 10−6 M dexamethasone. CD34 positive cells were expanded for
up to three weeks at low confluency (0.5–1×106 ml−1) to prevent their differentiation.
Differentiation of human macrophages
CD34 negative PBMCs were resuspended in RPMI complete (RPMI, 10% FBS, 100 μg mL
of streptomycin, 100 U ml−1 penicillin) supplemented with 10 ng ml−1 of human
recombinant macrophage colony stimulation factor (hrM-CSF, Peprotech, Rocky Hill, NJ) at
3×106 cells ml−1. We plated three ml of PBMC suspension in each well from a6-well plates
and monocytes were allowed to adhere to the plastic overnight at 37°C, 5% CO2. The
following day we carefully removed the supernatant and replaced it with 3ml of macrophage
differentiation medium (RPMI complete supplemented with 25 ng ml−1 of hrM-CSF).
Medium was changed every three days and macrophages were differentiated for 7–10 days.
Erythroid differentiation of human CD34positive hematopoietic progenitors
For erythroid differentiation, human CD34 positive cells being grown for up to three weeks
as described above, were washed with PBS and resuspended in human erythroid
differentiation medium (alpha-Minimum Essential Medium, 30% Hyclone FBS, 100 μg
ml−1 of streptomycin, 100 U ml−1 penicillin, 14μM 2-mercaptoethanol, 10 U ml−1 of hrEPO
and 1 ng ml−1 of SCF) at 106 cells ml−1. Erythroid differentiation was carried out for 8 days
in 6-well plates in the presence of absence of differentiated macrophages. During
differentiation, we kept the cells at 2 to 4×106 cells ml−1 by cell counting and refreshed the
medium at day 4, 6 and 8. Erythroid differentiation markers, cell cycle, apoptosis and
enucleation analysis were performed at these time points by flow cytometry (see below).
Human erythroid analyses by flow cytometry
Differentiating human erythroid cells were stained with the differentiating markers PE-
labeled CD117, FITC-labeled Glycophorin A (GPA), APC-conjugated CD44 (BD) and PE-
Cy5.5-conjugated Band3 for 15 minutes on ice. Cell cycle analysis was performed with the
APC-BrdU flow kit (BD) according to the provided protocol. Apoptosis stain with
AnnexinV and 7AAD was performed as described in the main text. All samples were
analyzed in a FACSCalibur (BD) instrument equipped with a dual-laser
Serum iron content
Serum iron and transferrin saturation were determined using the Iron/UIBC kit from Thermo
Electron (Melbourne, Australia) as previously described57.
Serum EPO levels
Serum EPO levels were determined by ELISA utilizing the kit from R&D Biosystems
(Minneapolis, MN) according to the instructions provided.
Immunohistochemistry analysis
Tissues were fixed in 10% buffered formalin and embedded in paraffin. Longitudinal
sections (4 um) were stained with hematoxylin and eosin (H&E) as previously described57.
Immunohistochemistry was performed on splenic sections from clodronate- and PBS-
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treated Hbbth3/+ mice using a F4/80 purified antibody on the BONDmaXAutomated
Immunostainer (Vision BioSystems, Melbourne, Australia).
Quantitative real-time PCR
We extracted RNA from liver samples utilizing the trizol reagent (Sigma, St. Louis, MO)
according to the instructions provided. We then quantified RNA samples and utilized 3 ug of
total RNA for retrotranscription using the SuperScript III kit (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Q-PCR for mouse hepcidin and the internal
control, GAPDH, were performed as previously described57.
Statistical analysis
Unless otherwise indicated, statistical differences were calculated with Student’s t test
(Microsoft Excel).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. WT mice depleted of macrophages have impaired recovery from induced-anemia
(a) Variation of hemoglobin and reticulocyte values in peripheral blood of phlebotomized
WT mice, treated with PBS- or clodronate-liposomes. Clod (day 0) and clod (day 4)
represent animals in which clodronate administration was started as day 0 or day 4 of
treatment, respectively. (b) Variation in splenomegaly in PBS- or clodronate-treated
phlebotomized WT mice. (c) Representative examples of CD71/Ter119 profiles from the
BM and spleen of non-phlebotomized WT (left panel), and phlebotomized PBS- (middle
panel) or clod (day 0) animals (right panel) at day 4 of treatment. Immature and mature
erythroid cells are identified respectively as CD71highTer119high and CD71LowTer119high
cells. (d) Representative example of CD71/Ter119 profiles from the BM and spleen of
phlebotomized PBS- or clod (day 4) animals, analyzed at day 6 of experiment. (e) Analysis
of apoptosis in the gate R1 (CD71highTer119low cells) defined in (d). For a more detailed
analysis refer to Supplementary Fig. 3. (f) Variation of hemoglobin levels following
phlebotomy in PBS- or clodronate-treated WT mice maintained on an iron-rich diet. In (a)
and (f) the results are presented as means ± SEMs of 4–18 age- and sex-matched mice for
each time point. Statistical significance is shown by * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.
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Figure 2. Clodronate treatment reverses phenotype in a mouse model of Polycythemia Vera
(a) Variation of hematocrit, RBC and reticulocyte values in peripheral blood of mice
affected by Polycythemia vera (PV) treated with PBS- or clodronate-liposomes. The results
are presented as means ± SEMs of 6 PBS- and 8 Clodronate-treated BMT mice for each
time point (** P ≤ 0.01, *** P ≤ 0.001 relative to PBS-controls). (b) Variation in
splenomegaly in PBS- or clodronate-treated PV mice. The graphic on top shows the average
spleen weight (± SEMs) for each group. (c) Upper panel shows a representative example of
CD71/Ter119 profiles from the bone marrow and spleen of PBS- or Clodronate-treated PV
animals, as described in Fig. 1. In these graphs an erythroid gate was established (R1) and
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events in R1 were plotted as CD44/Forward scatter (FSC) profiles50 (lower panel). Five
progressively more mature erythroid populations (I through V in lower left panel) were
defined. (d) Quantification of the data shown in (c). Graph on the left shows the percentage
of CD71highTer119high (C+T+) or CD71lowTer119high (C−T+) erythroid cells. On the right
is shown the percentage of cells in the populations I–V defined in the CD44/FSC plots. (e)
Total number or erythroid cells in the erythroid populations defined in (d). In (d) and (e) the
data is shown as means ± SEMs of 3 PBS- and 4 clodronate-treated animals. Statistical
significance is represented by * P ≤ 0.05, ** P ≤ 0.01 or *** P ≤ 0.001.
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Figure 3. Improvement of anemia and IE in Hbbth3/+ animals 40 hours after single clodronate
administration
(a) Hematological parameters 40 hours after a single IV administration of clodronate or PBS
liposomes. Hemoglobin, RBC counts and mean corpuscular hemoglobin (MCH) are
presented as means ± SEMs of 14 PBS- and 10 clodronate-treated mice. (b) Average (±
SEMs) spleen weight and illustrative spleen picture harvested from PBS-or clodronate-
treated Hbbth3/+ animals. (c) Representative example of CD71/Ter119 (upper panels) and
erythroid (R1 gate) CD44/FSC profiles (lower panels) from the BM and spleen of PBS- or
clodronate-treated Hbbth3/+ (th3/+) animals, as well as strain matched WT mice, similarly to
what is described in Fig. 2. (d) Represents the quantification of the data showed in (c). The
two graphs on the right show the percentage of immature CD71highTer119high (C+T+) or
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mature CD71lowTer119high (C−T+) erythroid cells in the CD71/Ter119. The two graphs on
the left show the percentage of cells in populations I–V defined in the CD44/FSC profiles.
The values are presented as means ± SEMs of 9–10 animals per group. Statistical
significance is represented by * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.
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Figure 4. Chronic clodronate administration improves anemia, IE and RBC phenotype in
Hbbth3/+ mice
(a) Variation in hematological parameters during three months of clodronate treatment.
Hemoglobin (g dl−1), RBC (number of cells x 106 μl−1), reticulocyte counts (number of
cells x 103μl−1), MCH (pg) and red cell distribution width (RDW shown in %) are presented
as means ± SEMs of 4–14 PBS- and 4–20 clodronate-treated Hbbth3/+ mice for each time
point. (b) RBC lifespan in PBS- or clodronate-treated WT or Hbbth3/+ (th3/+) mice. (c)
Survival of RBC obtained from PBS- (th3/+ PBS) or clodronate-treated (th3/+ clod)
Hbbth3/+ mice when transfused into GFP positive WT mice. Values in (b) and (c) are
presented as the average ± SEMs of at least 5 animals for each group. In (a)–(c) statistical
significance is defined by * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. (d) Blood smears stained
with May-Grunwald-Giemsa solution, showing RBCs morphology of representative WT,
PBS-treated (th3/+ PBS) and clodronate-treated Hbbth3/+ (th3/+ clod) mice at 2 months of
liposome treatment. (e) Quantification of RBC membrane-bound globins analyzed by triton
acetic acid urea (TAU) gel electrophoresis. The membrane fractions were prepared in
parallel from the same number of RBC for each group before loading. PBS- and clodronate-
treated Hbbth3/+ mice (th3/+) were analyzed at two months of treatment. Non-fractionated
RBC lysate was loaded in the control lane (STND). (f) Average weight of spleens harvested
from WT, and PBS- or clodronate-treated Hbbth3/+ (th3/+) animals at different time-points.
(g) Representative example of the CD71/Ter119 profiles from the BM and spleen of PBS- or
clodronate-treated β-thalassemic animals sacrificed at two months of treatment. (h) H&E
staining of splenic sections of WT, and PBS- or clodronate-treated Hbbth3/+ mice. Yellow
arrows show white pulp germinal centers. Results in (g) and (h) were reproduced for at least
three independent mice per group.
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Figure 5. Human macrophages promote proliferation and limit differentiation of primary
human erythroblasts
(a) Proliferation of human erythroid precursors when differentiated alone (EB) or in co-
cultures with human macrophages (EB+Mac). Graphs show a typical example of
proliferation of cells from a healthy donor, a JAK2V617F Polycythemia vera patient and a β-
thalassemic patient. Each condition was run in triplicate, the values representing the mean ±
standard deviation. (b) Cell cycle analysis of human erythroid cells at day 6 of
differentiation, when cultured alone (EB) or in the presence of macrophages (EB+Mac).
BrdU incorporation was used to determine the percentage of cells in S phase and 7AAD
linear analysis enabled quantification of DNA content. The different stages of cells cycle
(G0/G1, S and G2/M) are identified in the figures. (c) Proliferation of erythroblasts when
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cultured alone (EB), in co-culture with macrophages (EB+Mac) or in co-culture with
macrophages in a trans-well format (EB+Mac (TW)). Each condition was run in triplicate
and the values are presented as the mean ± standard deviation (*** P ≤ 0.001). In (a) and (c)
statistical significance was calculated by two-way ANOVA. (d) Erythroblast enucleation
when cultured alone (EB) or in the presence of macrophages (EB+Mac) was assessed at day
8 by DNA staining using DRAQ5.
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Figure 6. Model of macrophage function in normal and pathological erythropoiesis
(a) During steady state erythropoiesis macrophages mildly support erythroid development
but play a crucial function in maintenance of serum iron availability by controlling hepcidin
expression and iron recycling from senescent red cells. Upon macrophage depletion (right
panel), erythropoiesis is only slightly reduced, not significantly decreasing RBC production.
However, iron metabolism is impaired, leading to low iron availability, reduced hemoglobin
synthesis and low MCH. Anemia arises as a consequence of low MCH. (b) Model that
describes the (iron-independent) Stress Erythropoiesis Macrophage-supporting Activity
(SEMA) under conditions of elevated erythropoiesis associated with anemia, Epo
administration or Polycythemia vera due to the Jak2V617F mutation. Under these conditions,
SEMA supports erythropoiesis, functioning as a complement to EpoR/Jak2/Stat activation.
This allows for a high reticulocytosis and RBC production (left panel). If SEMA is
abrogated, erythroid expansion is markedly impaired leading to low reticulocytosis (right
panel). Moreover iron availability is also decreased further contributing for impaired
erythroid response. While the function of macrophages might be crucial during recovery
from anemia, it seems to play a decisive role for the pathophysiology of Polycythemia vera,
contributing for high erythrocytosis. (c) Contribution of macrophages to the
pathophysiology of β-thalassemia. In β-thalassemia, erythropoiesis is characterized by
increased erythroid proliferation and decreased differentiation, which is SEMA dependent
(left panel). Absence of macrophages leads to improvement of erythropoiesis by decreasing
the proliferation and improving the differentiation of erythroid progenitors (right panel). As
macrophage depletion is protracted overtime by repeated administration of clodronate,
erythroid iron availability decreases, further contributing for the phenotypic improvement of
β-thalassemic RBCs. (d) Model representing how macrophages support stress erythropoiesis
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in the erythroblastic island. EBs adhere to macrophages via different adhesion molecules
and these adhesive interactions, along with additional macrophage-secreted factors, activate
downstream signaling promoting EB survival, proliferation and controlling differentiation
(SEMA activity). In addition, complete support of stress erythropoiesis and hemoglobin
synthesis requires Epo and iron, the last one provided by the macrophages by recycling iron
from senescent RBCs. Peripheral blood (PB), bone marrow (BM), Spleen (Spl), Liver (Liv),
serum iron (SI) Hepcidin (Hpc), erythroid factor (EF) and iron recycling (Fe Rec) are shown
as abbreviations in the panels a–c. In a–c erythroid maturation is shown by the connecting
lines between each erythopoietic stage, up to RBC in the peripheral blood. Dashed lines
represent failure in erythroid differentiation. Arrow stroke represents intensity of each effect
(dashed arrows being the lowest).
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